Cargando…
First‐in‐human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple oral doses of SAR247799, a selective G‐protein‐biased sphingosine‐1 phosphate receptor‐1 agonist for endothelial protection
AIMS: SAR247799 is a selective G‐protein‐biased sphingosine‐1 phosphate receptor‐1 (S1P(1)) agonist with potential to restore endothelial function in vascular pathologies. SAR247799, a first‐in‐class molecule differentiated from previous S1P(1)‐desensitizing molecules developed for multiple sclerosi...
Autores principales: | Bergougnan, Luc, Armani, Sara, Golor, Georg, Tardat, Agnes, Vitse, Olivier, Hurbin, Fabrice, Scemama, Michel, Poitiers, Franck, Radzik, David, Gaudin, Christophe, Hovsepian, Lionel, Muslin, Anthony J., Kirkesseli, Stephane, Deutsch, Paul, Parkar, Ashfaq A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9328431/ https://www.ncbi.nlm.nih.gov/pubmed/32520410 http://dx.doi.org/10.1111/bcp.14422 |
Ejemplares similares
-
Endothelial‐protective effects of a G‐protein‐biased sphingosine‐1 phosphate receptor‐1 agonist, SAR247799, in type‐2 diabetes rats and a randomized placebo‐controlled patient trial
por: Bergougnan, Luc, et al.
Publicado: (2020) -
A G-protein-biased S1P(1) agonist, SAR247799, improved LVH and diastolic function in a rat model of metabolic syndrome
por: Evaristi, Maria Francesca, et al.
Publicado: (2022) -
A Randomized Study of the Relative Pharmacokinetics, Pharmacodynamics, and Safety of Alirocumab, a Fully Human Monoclonal Antibody to PCSK9, After Single Subcutaneous Administration at Three Different Injection Sites in Healthy Subjects
por: Lunven, Catherine, et al.
Publicado: (2014) -
A study on pharmacokinetics, pharmacodynamics and safety of lixisenatide in children and adolescents with type 2 diabetes
por: Barrientos‐Pérez, Margarita, et al.
Publicado: (2022) -
Interaction of microRNAs with sphingosine kinases, sphingosine-1 phosphate, and sphingosine-1 phosphate receptors in cancer
por: Xu, Guangmeng, et al.
Publicado: (2021)